Research Article
Peripheral Blood Inflammatory Markers Can Predict Benign and Malignant Thyroid Nodules
Table 1
Clinical characteristics of benign and malignant thyroid nodules.
| | Malignant nodules group (n = 140) | Benign nodule group (n = 374) | vaule |
| Gender (male/female) | 26/114 | 76/298 | 0.658 | Age (years) | 45.00 (36.00–54.75) | 50.00 (43.00–60.00) | <0.001 | Hypertension (yes/no) | 20/120 | 51/324 | 0.841 | Diabetes (yes/no) | 13/127 | 22/352 | 0.173 | Smoking (yes/no) | 9/131 | 30/344 | 0.544 | Solitary nodule (yes/no) | 48/92 | 129/245 | 0.965 | FT3 (pg/ml) | 3.20 (2.96–3.51) | 3.19 (2.90–3.45) | 0.223 | FT4 (ng/dl) | 1.30 (1.12–1.40) | 1.29 (1.17–1.42) | 0.780 | TSH (uIU/ml) | 1.62 (1.05–2.46) | 1.18 (1.77–2.71) | 0.187 | Leukocyte count (×109/L) | 5.65 (4.85–6.80) | 5.36 (4.45–6.32) | 0.006 | Erythrocyte count (×109/L) | 4.36 (4.18–4.66) | 4.36 (4.05–4.63) | 0.120 | Platelet count (×109/L) | 240.50 (204.25–279.50) | 228.50 (191.25–265.00) | 0.017 | Hemoglobin (g/L) | 131.00 (124.00–139.00) | 129.00 (120.00–137.00) | 0.071 | Neutrophil count (×109/L) | 3.40 (2.75–4.33) | 2.99 (2.35–3.76) | <0.001 | Lymphocyte count (×109/L) | 1.72 (1.41–2.06) | 1.73 (1.46–2.12) | 0.464 | NLR | 2.02 (1.34–2.73) | 1.66 (1.30–2.10) | <0.001 | PLR | 141.02 (105.43–182.20) | 127.11 (104.32–158.89) | 0.031 | SII (×109/L) | 457.68 (300.37–682.70) | 378.46 (275.02–494.03) | <0.001 | Diameter of nodule (cm) | 2.00 (1.00–3.60) | 2.50 (1.70–3.40) | 0.019 |
|
|
|